Please login to the form below

Not currently logged in
Email:
Password:

RVT-602

This page shows the latest RVT-602 news and features for those working in and with pharma, biotech and healthcare.

Takeda forms new women's health and cancer company

Takeda forms new women's health and cancer company

Myovant has also received an exclusive, commercial license for RVT-602, Takeda's oligopeptide kisspeptin receptor agonist for the treatment of female infertility.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics